-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Science and Technology Daily, Beijing, November 4 (Reporter Zhang Mengran) American researchers have discovered a key molecule in certain types of breast cancer that can prevent immune cells from entering the tumor to kill the cancer cells inside
The lead author of the paper, Dr.
Li Rong's team studied triple-negative breast cancer, which is an aggressive cancer that accounts for about 15% of all breast cancer cases
Researchers evaluated the impact of removing DDR1 in multiple preclinical models
Combining these new findings, researchers have developed a therapeutic DDR1 targeting antibody that can break that line of defense and help immune cells cross the barrier to kill tumors
Researchers say that the discovery of the important role of DDR1 in anti-cancer is a major advancement that may change the way of treatment
Editor-in-chief
Editor-in-chiefBreast cancer is the type of cancer that causes the most female deaths in the world, and triple-negative breast cancer is one of the most difficult subtypes, because compared to other breast cancers, it has a younger age of onset and is easier to metastasize-especially What is tricky in the medical profession is that the probability of recurrence after surgery is also higher